Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 291,476 shares of the biopharmaceutical company's stock after acquiring an additional 4,773 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.22% of Alnylam Pharmaceuticals worth $78,704,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. IFP Advisors Inc increased its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the period. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Silvercrest Asset Management Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $1,151,000. Blue Trust Inc. raised its holdings in Alnylam Pharmaceuticals by 33.9% in the 1st quarter. Blue Trust Inc. now owns 1,158 shares of the biopharmaceutical company's stock worth $313,000 after purchasing an additional 293 shares during the period. Finally, Bridger Management LLC boosted its position in Alnylam Pharmaceuticals by 11.2% during the fourth quarter. Bridger Management LLC now owns 41,182 shares of the biopharmaceutical company's stock worth $9,691,000 after purchasing an additional 4,160 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research note on Monday. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $340.00.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $7.71 during trading on Wednesday, hitting $329.77. The company had a trading volume of 967,737 shares, compared to its average volume of 856,062. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $339.59. The firm has a 50-day moving average price of $289.81 and a 200-day moving average price of $264.42. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The firm has a market cap of $43.00 billion, a PE ratio of -157.78 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period last year, the company earned ($0.16) EPS. The firm's revenue for the quarter was up 20.2% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.